Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


24.05.2021

1 BMC Gastroenterol
1 Dig Dis
1 Eur J Gastroenterol Hepatol
1 Gut
18 Inflamm Bowel Dis
3 J Crohns Colitis
1 JAMA
2 Lancet Gastroenterol Hepatol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Gastroenterol

  1. SAKELLARIOU S, Zouki DN, Ziogas DC, Pouloudi D, et al
    Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review.
    BMC Gastroenterol. 2021;21:227.
    PubMed         Abstract available


    Dig Dis

  2. RUEDA GARCIA JL, Suarez-Ferrer C, Poza Cordon J, Martin-Arranz E, et al
    Doppler Activity and Ultrasonographic Detection of Intra-Abdominal Fistulas Are Predictors of Surgery in Crohn's Disease.
    Dig Dis. 2021;39:204-210.
    PubMed         Abstract available


    Eur J Gastroenterol Hepatol

  3. VAN GENNEP S, Gielen ME, Rietdijk ST, de Boer NKH, et al
    Work productivity loss is determined by fatigue and reduced quality of life in employed inflammatory bowel disease patients: a prospective multicentre cohort study.
    Eur J Gastroenterol Hepatol. 2021 May 3. doi: 10.1097/MEG.0000000000002178.
    PubMed         Abstract available


    Gut

  4. HANSEN R, Meade S, Beattie RM, Auth MK, et al
    Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel.
    Gut. 2021;70:1044-1052.
    PubMed         Abstract available


    Inflamm Bowel Dis

  5. ALKHAYYAT M, Abureesh M, Almomani A, Abou Saleh M, et al
    Patients With Inflammatory Bowel Disease on Treatment Have Lower Rates of Celiac Disease.
    Inflamm Bowel Dis. 2021 May 14. pii: 6277368. doi: 10.1093.
    PubMed         Abstract available

  6. SQUIRE JD, Gonzalez-Estrada A, Caldera F, Farraye FA, et al
    COVID-19 Vaccination in Patients With Inflammatory Bowel Disease and History of Reaction to Injectable Therapies.
    Inflamm Bowel Dis. 2021 May 17. pii: 6276957. doi: 10.1093.
    PubMed        

  7. DE FRIAS GOMES CG, de Almeida ASR, Mendes CCL, Ellul P, et al
    Histological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis.
    Inflamm Bowel Dis. 2021 May 17. pii: 6276940. doi: 10.1093.
    PubMed         Abstract available

  8. HILLEY P, Gilmore R, Srinivasan A, Choy M, et al
    Combined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative Colitis.
    Inflamm Bowel Dis. 2021 May 17. pii: 6276958. doi: 10.1093.
    PubMed        

  9. FASOULAS K, Stergiou E, Soufleris K
    Ustekinumab for Crohn Disease With Severe Gastroduodenal Involvement.
    Inflamm Bowel Dis. 2021 May 17. pii: 6276944. doi: 10.1093.
    PubMed        

  10. SANTELLA C, Bitton A, Filliter C, Bessissow T, et al
    Anti-TNF Therapy and the Risk of Herpes Zoster Among Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2021 May 17. pii: 6276941. doi: 10.1093.
    PubMed         Abstract available


  11. Corrigendum to: Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity.
    Inflamm Bowel Dis. 2021 May 17. pii: 6276866. doi: 10.1093.
    PubMed        


  12. Erratum to: Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2021 May 17. pii: 6276685. doi: 10.1093.
    PubMed        

  13. GRAZIANO F, Macaluso FS, Cassata N, Citrano M, et al
    Pyoderma Gangrenosum in An Ulcerative Colitis Pediatric Patient During Vedolizumab Therapy Successfully Treated With Oral Cyclosporine.
    Inflamm Bowel Dis. 2021 May 18. pii: 6277715. doi: 10.1093.
    PubMed        

  14. DOS SANTOS CHM, Koga GA
    Response to the Letter to the Editor: "Pyoderma Gangrenosum in An Ulcerative Colitis Pediatric Patient During Vedolizumab Therapy Successfully Treated With Oral Cyclosporine".
    Inflamm Bowel Dis. 2021 May 18. pii: 6277711. doi: 10.1093.
    PubMed        

  15. IACUCCI M, Jeffery L, Acharjee A, Nardone OM, et al
    Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis-An Exploratory Study to Define Deep Remission.
    Inflamm Bowel Dis. 2021 May 21. pii: 6279651. doi: 10.1093.
    PubMed         Abstract available

  16. SACHAN A, Srivastava S, Shah J, Singh AK, et al
    Strongyloides Stercoralis in Acute Severe Ulcerative Colitis-A Triggering Nuisance or An Opportunistic Bystander?
    Inflamm Bowel Dis. 2021 May 21. pii: 6279668. doi: 10.1093.
    PubMed        

  17. HUSSAMEDDIN A, Sedano R, Ramsewak D, Driman D, et al
    Vedolizumab-Induced Endoscopic and Histologic Improvement in Gastric Menetrier's Disease in a Patient With Ulcerative Colitis.
    Inflamm Bowel Dis. 2021 May 21. pii: 6279703. doi: 10.1093.
    PubMed        

  18. HANZEL J, Jansen JM, Ter Steege RWF, Gecse KB, et al
    Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study.
    Inflamm Bowel Dis. 2021 May 20. pii: 6278840. doi: 10.1093.
    PubMed         Abstract available

  19. VAN WASSENAER EA, Benninga MA, van Limbergen JL, D'Haens GR, et al
    Intestinal Ultrasound in Pediatric Inflammatory Bowel Disease: Promising, but Work in Progress.
    Inflamm Bowel Dis. 2021 May 20. pii: 6278841. doi: 10.1093.
    PubMed         Abstract available

  20. MCCURDY J, Siw KCK, Kandel R, Larrigan S, et al
    The Effectiveness and Safety of Hyperbaric Oxygen Therapy in Various Phenotypes of Inflammatory Bowel Disease: Systematic Review With Meta-analysis.
    Inflamm Bowel Dis. 2021 May 18. pii: 6277724. doi: 10.1093.
    PubMed         Abstract available

  21. CHEAH M, Wilson A, Solh Z, Khanna R, et al
    IgA-Mediated Warm Autoimmune Hemolytic Anemia as an Extraintestinal Manifestation in a Patient With Crohn Disease on Vedolizumab.
    Inflamm Bowel Dis. 2021 May 18. pii: 6277765. doi: 10.1093.
    PubMed        

  22. VERDE A, Grammegna A, Petrone E, Mastrominico A, et al
    Crohn-Like Colitis in a Young Boy With Hirschsprung Disease.
    Inflamm Bowel Dis. 2021 May 18. pii: 6277720. doi: 10.1093.
    PubMed        


    J Crohns Colitis

  23. BERTE' R, Mazza S, Stefanucci MR, Noviello D, et al
    Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.
    J Crohns Colitis. 2021;15:864-868.
    PubMed         Abstract available

  24. WEISSMAN S, Patel K, Kolli S, Lipcsey M, et al
    Obesity in Inflammatory Bowel Disease is Associated with Early Readmissions characterized by an Increased Systems and Patient-level Burden.
    J Crohns Colitis. 2021 May 17. pii: 6276891. doi: 10.1093.
    PubMed         Abstract available

  25. DHERI AK, Kuenzig ME, Mack DR, Murthy SK, et al
    Shifting health care use from hospitalizations and surgeries to outpatient visits in children with inflammatory bowel disease: a population-based cohort study from Ontario, Canada.
    J Crohns Colitis. 2021 May 21. pii: 6279878. doi: 10.1093.
    PubMed         Abstract available


    JAMA

  26. SYVERSEN SW, Goll GL, Jorgensen KK, Sandanger O, et al
    Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    JAMA. 2021;325:1744-1754.
    PubMed         Abstract available


    Lancet Gastroenterol Hepatol

  27. DANESE S, Parigi TL, Peyrin-Biroulet L, Ghosh S, et al
    Defining difficult-to-treat inflammatory bowel disease: why and how.
    Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00141.
    PubMed        

  28. ALSOUD D, Verstockt B, Fiocchi C, Vermeire S, et al
    Breaking the therapeutic ceiling in drug development in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00065.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: